LeMaitre Vascular Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
Für LeMaitre Vascular wird ein Gewinn- und Umsatzwachstum von 9.5% bzw. 8.8% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 8.3% pro Jahr steigen soll.
Wichtige Informationen
9.5%
Wachstumsrate der Gewinne
8.29%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 16.1% |
| Wachstumsrate der Einnahmen | 8.8% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 14 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Analyseartikel • Mar 02
Earnings Update: Here's Why Analysts Just Lifted Their LeMaitre Vascular, Inc. (NASDAQ:LMAT) Price Target To US$105
Shareholders might have noticed that LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) filed its yearly result this time last...Analyseartikel • Nov 02
LeMaitre Vascular, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
As you might know, LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) just kicked off its latest quarterly results with some very...Recent updates
Narrativ-Update • Apr 27
LMAT: Future Cash Returns And Operating Leverage May Sustain Current Premium
Narrative Update on LeMaitre Vascular The updated analyst price target for LeMaitre Vascular moves to $117 from $108. This reflects analysts' focus on recent double digit organic growth, margin expansion, strong cash flow, and better than expected Q4 results with operating leverage.Narrativ-Update • Apr 13
LMAT: Future Margin Discipline And Cash Returns May Support Current Premium
Narrative Update on LeMaitre Vascular The updated analyst price target for LeMaitre Vascular now reflects a modestly higher fair value estimate of about $111.22. This is supported by Street research that highlights continued double digit organic sales growth, material margin expansion, strong cash flow and operating leverage in the wake of better than expected Q4 results and guidance.Narrativ-Update • Mar 29
LMAT: Future Cash Returns And Margin Discipline May Sustain Current Premium
Narrative Update Analysts have raised LeMaitre Vascular's price targets by $10 to $12, now in a $105 to $117 range. They cite double digit organic revenue growth, margin expansion, strong cash flow, better than expected Q4 results, and operating leverage.Narrativ-Update • Mar 14
LMAT: Future Margin Execution And Capital Returns May Support Current Premium
Narrative Update on LeMaitre Vascular Our analyst fair value estimate for LeMaitre Vascular has been lifted from $109.22 to $111.00, reflecting updated price targets from $95 to $105 and from $108 to $117 as analysts point to double digit organic growth, margin expansion, and operating leverage following better than expected Q4 results and guidance. Analyst Commentary Recent price target increases to $105 and $117 signal that bullish analysts are incorporating stronger fundamentals into their models following the latest Q4 print and guidance.Narrativ-Update • Feb 28
LMAT: Future Margin Gains And Capital Returns May Sustain Current Premium
Analysts have increased their implied fair value estimate for LeMaitre Vascular by about $4 to roughly $109, citing recent price target increases to $105 and $117 that they attribute to double-digit organic sales growth, margin expansion and operating leverage. Analyst Commentary Bullish Takeaways Bullish analysts point to double digit organic sales growth as a key support for their higher fair value views, seeing current revenue trends as consistent with a premium valuation versus slower growing peers.Seeking Alpha • Feb 27
LeMaitre Vascular: The Compounder Keeps Compounding
Summary LeMaitre Vascular delivered strong Q4 and FY 2025 results, with 16% YoY sales growth and broad-based margin expansion. Artegraft’s international rollout exceeded expectations, with 2025 sales doubling guidance and a projected $10M in 2026. This could drive earnings growth for years to come. LMAT maintains a robust $190M net cash position and recently increased its dividend by 25%. The board has also authorized a $100M share repurchase program. Operating leverage, pricing power, and international expansion are all key drivers in raising my price target to $116-$130 for year-end 2026. I reiterate my Buy rating. Read the full article on Seeking AlphaAnalyseartikel • Feb 06
Here's Why LeMaitre Vascular (NASDAQ:LMAT) Has Caught The Eye Of Investors
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analyseartikel • Jan 03
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Shares May Have Run Too Fast Too Soon
With a price-to-earnings (or "P/E") ratio of 34.1x LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) may be sending very bearish...Analyseartikel • Oct 26
Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to...Analyseartikel • Aug 30
Here's Why LeMaitre Vascular (NASDAQ:LMAT) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyseartikel • Aug 06
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Could Be 25% Above Their Intrinsic Value Estimate
Key Insights LeMaitre Vascular's estimated fair value is US$68.59 based on 2 Stage Free Cash Flow to Equity Current...Analyseartikel • Jul 18
Is LeMaitre Vascular (NASDAQ:LMAT) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Jun 18
Earnings Not Telling The Story For LeMaitre Vascular, Inc. (NASDAQ:LMAT)
LeMaitre Vascular, Inc.'s ( NASDAQ:LMAT ) price-to-earnings (or "P/E") ratio of 40.5x might make it look like a strong...Analyseartikel • Apr 24
Should You Be Adding LeMaitre Vascular (NASDAQ:LMAT) To Your Watchlist Today?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analyseartikel • Apr 12
Does LeMaitre Vascular (NASDAQ:LMAT) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Mar 31
LeMaitre Vascular (NASDAQ:LMAT) Will Want To Turn Around Its Return Trends
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...Analyseartikel • Mar 11
LeMaitre Vascular's (NASDAQ:LMAT) Shareholders Will Receive A Bigger Dividend Than Last Year
LeMaitre Vascular, Inc.'s ( NASDAQ:LMAT ) dividend will be increasing from last year's payment of the same period to...Analyseartikel • Mar 02
Earnings Update: Here's Why Analysts Just Lifted Their LeMaitre Vascular, Inc. (NASDAQ:LMAT) Price Target To US$105
Shareholders might have noticed that LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) filed its yearly result this time last...Analyseartikel • Feb 04
When Should You Buy LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
While LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) might not have the largest market cap around , it received a lot of...Analyseartikel • Jan 22
We Ran A Stock Scan For Earnings Growth And LeMaitre Vascular (NASDAQ:LMAT) Passed With Ease
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Seeking Alpha • Jan 15
LeMaitre Vascular: Losing Steam
Summary LeMaitre Vascular, Inc. has seen a 65% stock rise over 12 months but trades at high valuations with decelerating growth projections. Q3 results showed strong performance with 46% profit growth and 15.7% revenue increase, driven by grafts, patches, and carotid shunts. The stock has dipped some 15% recently. Buy the dip? An analysis around LeMaitre Vascular follows in the paragraphs below. Read the full article on Seeking AlphaAnalyseartikel • Jan 09
A Look At The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Key Insights LeMaitre Vascular's estimated fair value is US$96.24 based on 2 Stage Free Cash Flow to Equity Current...Analyseartikel • Dec 22
LeMaitre Vascular (NASDAQ:LMAT) Has More To Do To Multiply In Value Going Forward
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analyseartikel • Nov 24
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) 26% Price Boost Is Out Of Tune With Earnings
LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) shares have had a really impressive month, gaining 26% after a shaky period...Seeking Alpha • Nov 03
LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story
Summary LeMaitre continues to expand in the peripheral vascular disease market, with recent revenue gains driven by premium pricing and international growth. Its strong dividend growth of 14.3% this year and double-digit CAGR over the past five years are particularly appealing. With a high-margin, low-competition niche and accelerating geographic expansion, LeMaitre remains well-positioned for sustained growth. Read the full article on Seeking AlphaAnalyseartikel • Nov 02
LeMaitre Vascular, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
As you might know, LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) just kicked off its latest quarterly results with some very...Analyseartikel • Oct 08
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Potentially Undervalued?
While LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) might not have the largest market cap around , it saw a double-digit...Analyseartikel • Sep 17
Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...
Neues Narrativ • Sep 11
Expanding Market Reach And Calculated Acquisitions Set To Fuel Robust Revenue And Earnings Growth
Expansion in North America and new regulatory approvals in Europe and Asia-Pacific indicate potential revenue growth from increased market share and customer reach.Analyseartikel • Sep 04
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Price In Tune With Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...Analyseartikel • Aug 22
If EPS Growth Is Important To You, LeMaitre Vascular (NASDAQ:LMAT) Presents An Opportunity
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Jul 23
LeMaitre Vascular: A Small Cap With Best-In-Industry Growth
Summary I outline why LeMaitre Vascular is my top choice in the Health Care Equipment industry and one of the best small caps in the sector. LeMaitre has shown incredible revenue and EPS growth since its IPO and also offers a well-supported, fast-growing dividend. Despite a seemingly high valuation, further growth is expected. Read the full article on Seeking AlphaAnalyseartikel • Jul 12
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$85.0 Based On Its Intrinsic Value?
Key Insights LeMaitre Vascular's estimated fair value is US$70.02 based on 2 Stage Free Cash Flow to Equity Current...Analyseartikel • Jun 18
Is There Now An Opportunity In LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
LeMaitre Vascular, Inc. ( NASDAQ:LMAT ), might not be a large cap stock, but it led the NASDAQGM gainers with a...Analyseartikel • Jun 05
Return Trends At LeMaitre Vascular (NASDAQ:LMAT) Aren't Appealing
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...Analyseartikel • May 02
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Popularity With Investors Is Clear
With a price-to-earnings (or "P/E") ratio of 49.8x LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) may be sending very bearish...Analyseartikel • Apr 04
Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analyseartikel • Feb 29
Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Key Insights The projected fair value for LeMaitre Vascular is US$68.32 based on 2 Stage Free Cash Flow to Equity...Analyseartikel • Jan 19
What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?
LeMaitre Vascular, Inc. ( NASDAQ:LMAT ), might not be a large cap stock, but it led the NASDAQGM gainers with a...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 333 | 83 | 92 | 118 | 4 |
| 12/31/2027 | 306 | 76 | 86 | 94 | 9 |
| 12/31/2026 | 280 | 69 | 70 | 80 | 9 |
| 3/31/2026 | 256 | 62 | 79 | 87 | N/A |
| 12/31/2025 | 250 | 58 | 74 | 81 | N/A |
| 9/30/2025 | 241 | 53 | 66 | 73 | N/A |
| 6/30/2025 | 235 | 47 | 52 | 59 | N/A |
| 3/31/2025 | 226 | 45 | 41 | 48 | N/A |
| 12/31/2024 | 220 | 44 | 37 | 44 | N/A |
| 9/30/2024 | 213 | 41 | 33 | 40 | N/A |
| 6/30/2024 | 206 | 38 | 32 | 37 | N/A |
| 3/31/2024 | 200 | 34 | 33 | 40 | N/A |
| 12/31/2023 | 193 | 30 | 29 | 37 | N/A |
| 9/30/2023 | 186 | 27 | 23 | 30 | N/A |
| 6/30/2023 | 177 | 25 | 19 | 26 | N/A |
| 3/31/2023 | 169 | 21 | 18 | 23 | N/A |
| 12/31/2022 | 162 | 21 | 22 | 25 | N/A |
| 9/30/2022 | 160 | 21 | 24 | 26 | N/A |
| 6/30/2022 | 160 | 22 | 29 | 33 | N/A |
| 3/31/2022 | 158 | 27 | 29 | 34 | N/A |
| 12/31/2021 | 154 | 27 | 30 | 35 | N/A |
| 9/30/2021 | 152 | 28 | 39 | 44 | N/A |
| 6/30/2021 | 151 | 29 | 40 | 44 | N/A |
| 3/31/2021 | 135 | 24 | 37 | 40 | N/A |
| 12/31/2020 | 129 | 21 | 32 | 35 | N/A |
| 9/30/2020 | 122 | 19 | 23 | 26 | N/A |
| 6/30/2020 | 115 | 16 | 13 | 17 | N/A |
| 3/31/2020 | 119 | 18 | 12 | 16 | N/A |
| 12/31/2019 | 117 | 18 | N/A | 14 | N/A |
| 9/30/2019 | 115 | 19 | N/A | 15 | N/A |
| 6/30/2019 | 111 | 18 | N/A | 15 | N/A |
| 3/31/2019 | 108 | 23 | N/A | 16 | N/A |
| 12/31/2018 | 106 | 23 | N/A | 20 | N/A |
| 9/30/2018 | 103 | 21 | N/A | 20 | N/A |
| 6/30/2018 | 104 | 22 | N/A | 24 | N/A |
| 3/31/2018 | 103 | 18 | N/A | 24 | N/A |
| 12/31/2017 | 101 | 17 | N/A | 23 | N/A |
| 9/30/2017 | 98 | 15 | N/A | 20 | N/A |
| 6/30/2017 | 96 | 14 | N/A | 18 | N/A |
| 3/31/2017 | 93 | 12 | N/A | 18 | N/A |
| 12/31/2016 | 89 | 11 | N/A | 17 | N/A |
| 9/30/2016 | 86 | 11 | N/A | 17 | N/A |
| 6/30/2016 | 82 | 9 | N/A | 14 | N/A |
| 3/31/2016 | 79 | 9 | N/A | 13 | N/A |
| 12/31/2015 | 78 | 8 | N/A | 11 | N/A |
| 9/30/2015 | 76 | 7 | N/A | 10 | N/A |
| 6/30/2015 | 74 | 6 | N/A | 9 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: LMATDas prognostizierte Gewinnwachstum (9.5% pro Jahr) liegt über der Sparquote (3.5%).
Ertrag vs. Markt: LMATDie Erträge des Unternehmens (9.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (16.7% pro Jahr).
Hohe Wachstumserträge: LMATDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: LMATDie Einnahmen des Unternehmens (8.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.7% pro Jahr).
Hohe Wachstumseinnahmen: LMATDie Einnahmen des Unternehmens (8.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von LMAT in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/22 01:06 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
LeMaitre Vascular, Inc. wird von 20 Analysten beobachtet. 9 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Jan Wald | Benchmark Company |
| Raymond Myers | Benchmark Company |